FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--
Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it was added to the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 22, 2018. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
“Following our successful IPO earlier this year, we believe inclusion in the Russell Microcap® Index will enable us to further broaden our growing investor base, ultimately expanding our visibility and awareness. We are grateful to have been added and look forward to utilizing the visibility to build shareholder value as we continue to advance the development and commercialization of our flagship product, the Pure-Vu® System,” said Mark Pomeranz, CEO of Motus GI.
FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
The Russell Microcap® Index is one of the most widely used small cap indexes by institutional investors. Approximately 1,500 securities are included in the Russell Microcap® Index, with market capitalizations ranging from $30 million to $1.1 billion. For more information on the Russell Microcap® Index and the index reconstitution, go to the Russell Reconstitution section on the FTSE Russell website.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission.